KOREAN DRUG CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,230 KRW | +0.32% |
|
+0.48% | -13.23% |
| 2023 | Korean Drug Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
| 2021 | Tranche Update on Korean Drug Co., Ltd.'s Equity Buyback Plan announced on December 14, 2020. | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 78,785 | 78,457 | 112,394 | 97,444 | 85,441 | 78,348 |
| Enterprise Value (EV) 1 | 70,163 | 67,012 | 90,216 | 69,618 | 59,106 | 61,660 |
| P/E ratio | 12 x | 20.1 x | 15.2 x | 10.8 x | 7.15 x | -15.7 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 1.51 x | 1.41 x | 1.68 x | 1.31 x | 1.07 x | 0.96 x |
| EV / Revenue | 1.35 x | 1.21 x | 1.35 x | 0.93 x | 0.74 x | 0.76 x |
| EV / EBITDA | 15.4 x | 14.6 x | 7.28 x | 5.47 x | 3.76 x | 7.28 x |
| EV / FCF | 17.1 x | 27.2 x | 9.59 x | 11.2 x | -21.8 x | 29.5 x |
| FCF Yield | 5.83% | 3.68% | 10.4% | 8.97% | -4.58% | 3.39% |
| Price to Book | 1.25 x | 1.2 x | 1.58 x | 1.26 x | 1 x | 1 x |
| Nbr of stocks (in thousands) | 10,912 | 10,912 | 10,912 | 10,912 | 10,912 | 10,912 |
| Reference price 2 | 7,220 | 7,190 | 10,300 | 8,930 | 7,830 | 7,180 |
| Announcement Date | 3/1/19 | 2/29/20 | 3/1/21 | 3/1/22 | 3/1/23 | 2/29/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 52,028 | 55,529 | 66,789 | 74,466 | 79,984 | 81,375 |
| EBITDA 1 | 4,560 | 4,601 | 12,394 | 12,736 | 15,712 | 8,469 |
| EBIT 1 | 3,527 | 3,416 | 11,039 | 11,266 | 14,329 | 6,720 |
| Operating Margin | 6.78% | 6.15% | 16.53% | 15.13% | 17.91% | 8.26% |
| Earnings before Tax (EBT) 1 | 8,129 | 4,450 | 9,240 | 11,321 | 14,685 | 8,265 |
| Net income 1 | 6,562 | 3,895 | 7,360 | 9,042 | 11,809 | -4,917 |
| Net margin | 12.61% | 7.01% | 11.02% | 12.14% | 14.76% | -6.04% |
| EPS 2 | 601.8 | 357.3 | 677.4 | 827.6 | 1,095 | -456.0 |
| Free Cash Flow 1 | 4,093 | 2,467 | 9,411 | 6,243 | -2,709 | 2,092 |
| FCF margin | 7.87% | 4.44% | 14.09% | 8.38% | -3.39% | 2.57% |
| FCF Conversion (EBITDA) | 89.76% | 53.62% | 75.93% | 49.02% | - | 24.71% |
| FCF Conversion (Net income) | 62.37% | 63.34% | 127.88% | 69.05% | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/1/19 | 2/29/20 | 3/1/21 | 3/1/22 | 3/1/23 | 2/29/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 8,621 | 11,446 | 22,178 | 27,826 | 26,335 | 16,688 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 4,093 | 2,467 | 9,411 | 6,243 | -2,709 | 2,092 |
| ROE (net income / shareholders' equity) | 11% | 6.09% | 10.8% | 12.3% | 14.6% | -6.08% |
| ROA (Net income/ Total Assets) | 3.15% | 2.87% | 8.67% | 8.19% | 9.78% | 4.56% |
| Assets 1 | 208,029 | 135,739 | 84,905 | 110,412 | 120,737 | -107,829 |
| Book Value Per Share 2 | 5,759 | 5,971 | 6,507 | 7,112 | 7,855 | 7,147 |
| Cash Flow per Share 2 | 503.0 | 576.0 | 649.0 | 449.0 | 318.0 | 1,084 |
| Capex 1 | 1,300 | 3,052 | 738 | 1,146 | 6,093 | 5,814 |
| Capex / Sales | 2.5% | 5.5% | 1.11% | 1.54% | 7.62% | 7.14% |
| Announcement Date | 3/1/19 | 2/29/20 | 3/1/21 | 3/1/22 | 3/1/23 | 2/29/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -13.23% | 50.47M | |
| +21.60% | 44.15B | |
| +23.03% | 23.02B | |
| +20.18% | 15.33B | |
| +12.26% | 13.74B | |
| +52.79% | 12.16B | |
| -10.02% | 6.84B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +13.88% | 5.66B |
- Stock Market
- Equities
- A014570 Stock
- Financials Korean Drug Co., Ltd.
